Infections in the era of immunobiologicals
Abstract Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient q...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia
2024-04-01
|
| Series: | Anais Brasileiros de Dermatologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962024000200167&lng=en&tlng=en |
| _version_ | 1797205759149211648 |
|---|---|
| author | Ricardo Romiti André Luís da Silva Hirayama Adriana Maria Porro Heitor de Sá Gonçalves Luciane Donida Bartoli Miot Sandra Maria Barbosa Durães Silvio Alencar Marques |
| author_facet | Ricardo Romiti André Luís da Silva Hirayama Adriana Maria Porro Heitor de Sá Gonçalves Luciane Donida Bartoli Miot Sandra Maria Barbosa Durães Silvio Alencar Marques |
| author_sort | Ricardo Romiti |
| collection | DOAJ |
| description | Abstract Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios. |
| first_indexed | 2024-04-24T08:56:13Z |
| format | Article |
| id | doaj.art-70761bf42f3a4fbb82d4fb198e78ea31 |
| institution | Directory Open Access Journal |
| issn | 0365-0596 |
| language | English |
| last_indexed | 2024-04-24T08:56:13Z |
| publishDate | 2024-04-01 |
| publisher | Sociedade Brasileira de Dermatologia |
| record_format | Article |
| series | Anais Brasileiros de Dermatologia |
| spelling | doaj.art-70761bf42f3a4fbb82d4fb198e78ea312024-04-16T07:40:57ZengSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia0365-05962024-04-0199216718010.1016/j.abd.2023.08.004Infections in the era of immunobiologicalsRicardo Romitihttps://orcid.org/0000-0003-0165-3831André Luís da Silva Hirayamahttps://orcid.org/0000-0002-6276-3551Adriana Maria Porrohttps://orcid.org/0000-0003-0736-4790Heitor de Sá Gonçalveshttps://orcid.org/0000-0001-9062-2580Luciane Donida Bartoli Miothttps://orcid.org/0000-0002-2388-7842Sandra Maria Barbosa Durãeshttps://orcid.org/0000-0001-9743-5067Silvio Alencar Marqueshttps://orcid.org/0000-0002-5512-4700Abstract Immunobiologicals represent an innovative therapeutic option in dermatology. They are indicated in severe and refractory cases of different diseases when there is contraindication, intolerance, or failure of conventional systemic therapy and in cases with significant impairment of patient quality of life. The main immunobiologicals used in dermatology basically include inhibitors of tumor necrosis factor-alpha (anti-TNF), inhibitors of interleukin-12 and -23 (anti-IL12/23), inhibitors of interleukin-17 and its receptor (anti-IL17), inhibitors of interleukin-23 (anti-IL23), rituximab (anti-CD20 antibody), dupilumab (anti-IL4/IL13) and intravenous immunoglobulin. Their immunomodulatory action may be associated with an increase in the risk of infections in the short and long term, and each case must be assessed individually, according to the risk inherent to the drug, the patient general condition, and the need for precautions. This article will discuss the main risks of infection associated with the use of immunobiologicals, addressing the risk in immunocompetent and immunosuppressed patients, vaccination, fungal infections, tuberculosis, leprosy, and viral hepatitis, and how to manage the patient in the most diverse scenarios.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962024000200167&lng=en&tlng=enBiological productsHepatitis, viral, humanLeprosyMycosis fungoidesTuberculosisVaccinationPsoriasis |
| spellingShingle | Ricardo Romiti André Luís da Silva Hirayama Adriana Maria Porro Heitor de Sá Gonçalves Luciane Donida Bartoli Miot Sandra Maria Barbosa Durães Silvio Alencar Marques Infections in the era of immunobiologicals Anais Brasileiros de Dermatologia Biological products Hepatitis, viral, human Leprosy Mycosis fungoides Tuberculosis Vaccination Psoriasis |
| title | Infections in the era of immunobiologicals |
| title_full | Infections in the era of immunobiologicals |
| title_fullStr | Infections in the era of immunobiologicals |
| title_full_unstemmed | Infections in the era of immunobiologicals |
| title_short | Infections in the era of immunobiologicals |
| title_sort | infections in the era of immunobiologicals |
| topic | Biological products Hepatitis, viral, human Leprosy Mycosis fungoides Tuberculosis Vaccination Psoriasis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962024000200167&lng=en&tlng=en |
| work_keys_str_mv | AT ricardoromiti infectionsintheeraofimmunobiologicals AT andreluisdasilvahirayama infectionsintheeraofimmunobiologicals AT adrianamariaporro infectionsintheeraofimmunobiologicals AT heitordesagoncalves infectionsintheeraofimmunobiologicals AT lucianedonidabartolimiot infectionsintheeraofimmunobiologicals AT sandramariabarbosaduraes infectionsintheeraofimmunobiologicals AT silvioalencarmarques infectionsintheeraofimmunobiologicals |